Wockhardt puts its marketing division ‘Merind’ on sale

07 Sep 2009 Evaluate

Wockhardt is learnt to have put its marketing division of pharmaceutical

formulations, Merind, up for sale. MNCs have shown interest in picking up the division, for which Wockhardt is learnt to have put a price tag of nearly Rs 800 crore, according to sources. Top line and EBIDTA of Merind could be Rs 300-350 crore and Rs 60-70 crore, respectively, according to sources. Wockhardt does not reveal the size of Merind’s business in its balance sheet since it is a business division.

The proposed sale is part of the troubled pharma company’s attempt to raise funds to repay debts totalling Rs 3,400 crore. Wockhardt recently sold its German subsidiary, Esparma, for Rs 120 crore, animal healthcare business for Rs 170 crore and its nutritional division for $130 million ( approximately Rs 635 crore) to raise funds. The company’s promoters, the Khorakiwala family, also sold 10 Wockhardt hospitals to Fortis for Rs 909 crore.

Merind’s is learnt to be the second largest marketing division within Wockhardt, selling more than 26 brands including top brands like Decdan, Tryptomer and Libotryb. These three brands had annual sales of Rs 21.5 crore, Rs 19.5 crore and Rs 13 crore respectively. It employs over 300 people. crackcrack

Wockhardt Share Price

1481.40 20.25 (1.39%)
27-Dec-2024 13:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1863.85
Dr. Reddys Lab 1393.30
Cipla 1510.00
Lupin 2232.50
Zydus Lifesciences 980.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.